Geron (GERN) Stifel 2024 Healthcare Conference summary

Opening remarks and forward-looking statements

• Leadership transition noted due to illness, with forward-looking statements highlighted and reference to risk factors in SEC filings.

• Expressed optimism about recent performance and future prospects, with CFO to address financial matters.

Recent performance and financial position

• Achieved a strong first quarter post-launch of RYTELO and imetelstat in low-risk MDS.

• Secured $125M synthetic royalty deal and $250M debt deal, enhancing ability to invest in future growth and EU commercialization.

• Quarterly revenue of $28M exceeded expectations, with demand increasing month over month and coverage of 45% of targeted accounts.

Commercial launch and market dynamics

• Demand is growing, with two-thirds of patients from community settings and one-third from academic centers.

• Community physicians are managing cytopenias effectively, supported by nurse and medical science teams.

• Early data shows uptake across all key patient segments, including ESA ineligible, RS positive, and RS negative patients.

• Strong competitive positioning expected in second-line RS negative population, where alternatives are limited.